Track 12: Value and Access
The healthcare landscape is evolving into one assessed on value, and there is a need to understand the impact of this movement on all stakeholders – providers, payers, biopharma, and ultimately patients. The Value and Access track will bring together global regulators, industry leaders, patients, and payers who will facilitate discussions and address questions such as:
- What information and evidence is being used to define value?
- Who is making or influencing access decisions?
- How can real-world data be leveraged to drive access to medicines?
- What are the regulatory and legal considerations surrounding value-based contracting conversations with payers?
Sessions in Value and Access
Monday, June 28
- Market Access, Medical Affairs, and Regulatory Affairs Functions Working Together to Address Payor and Regulatory Requirements
- How Can We Compliantly Exchange Pre-Approval Information with Payers
Tuesday, June 29
- Remaining Challenges to the COVID-19 Response
- How Can Real-World Evidence be Communicated Compliantly to Payers or Healthcare Providers?
Wednesday, June 30
- The Promise of Digital Health Tools in Delivering Value to Patients and Health Systems
- Beyond Cancer: Why Pharma is Moving to High Quality Real-World Data for Immunology and Other Chronic Diseases
- Who Should Pay for Expanded Access?
Thursday, July 1
- Basics of Healthcare Reform for Life Sciences Professionals
- Needs Assessment: Key Factor in Value-Based Funding for Medical Device Innovation
- Early Access Programs as Real-World Data Generators: An Additional Source of Data in the Pre-Approval Phase
Who is This Track Designed For?
Professionals involved in: Health economics outcomes, statistics, data modeling, clinical research, post-marketing, regulatory affairs, and health economy.